MYNZ Mainz Biomed N.V.: Utang jangka cendhak perusahaan

Mainz Biomed N.V. (MYNZ) develops genetic systems for the early detection of oncology, however, high promotion expenses coupled with operating losses complicate cash flow forecasting. The business relies on the supply of colorectal tests to clinics in the US and Europe. The asset's market value dynamics reflect the 0.00 indicator, while dumping and the struggle for insurance coverage limit pricing power.

For Mainz Biomed N.V. (MYNZ), which is protected by the humanitarian status of oncology diagnostics in the EU and US, aggregate short obligations on GURU.Markets reflect the dynamics of operating liabilities with maturities of up to one year. This indicator measures short-term liquidity through the total amount of current loans and borrowings, allowing investors to assess the company's capital resilience to sudden debt spikes in the absence of geopolitical risks.